Jazz Pharmaceuticals JAZZ Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's change in accrued liabilities?
- Jazz Pharmaceuticals (JAZZ) reported change in accrued liabilities of -$7.9M in Q1 2026.
- How has Jazz Pharmaceuticals's change in accrued liabilities changed year-over-year?
- Jazz Pharmaceuticals's change in accrued liabilities decreased by 104.4% year-over-year, from $181M to -$7.9M.
- What is the long-term trend for Jazz Pharmaceuticals's change in accrued liabilities?
- Over 2 years (2021 to 2025), Jazz Pharmaceuticals's change in accrued liabilities has grown at a -26.4% compound annual growth rate (CAGR), from $142.36M to $77.1M.
- What does change in accrued liabilities mean?
- The change in short-term obligations for expenses incurred but not yet paid.
- How do you interpret change in accrued liabilities?
- An increase in accruals acts as a source of cash, while a decrease acts as a use of cash.
- How does change in accrued liabilities compare across companies?
- Common across all industries; levels depend on the timing of recurring operational costs.